Australian Clinical Labs Ltd (ASX: ACL) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Australian Clinical Labs Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $379.57 million
P/E Ratio 14.66
Dividend Yield 6.16%
Shares Outstanding 187.90 million
Earnings per share 0.141
Dividend per share 0.13
Year To Date Return -23.36%
Earnings Yield 6.82%
Franking 100%
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Australian Clinical Labs Ltd (ASX: ACL)
Latest News

Two boys with cardboard rockets strapped to their backs, indicating two ASX companies with rocketing share prices
Share Gainers

Catch these fast-rising 2 ASX shares before it's too late: Celeste

This pair of stocks rocketed up in February during reporting season, but are still great value for those willing to…

Read more »

three children wearing superhero costumes, complete with masks, pose with hands on hips wearing capes and sneakers on a running track.
Small Cap Shares

'Very attractive valuations': Experts name 3 small-cap ASX shares to buy

If you agree that smaller companies are ready to roar again in 2023, here is a trio of stocks to…

Read more »

A older man and younger man rest, exhausted but happy after a good boxing session.
Cheap Shares

2 hammered ASX shares to buy before they rise again: Celeste

If you're purchasing a house you'd want it for the lowest price. So why is it any different for stocks?

Read more »

A male Avita Medical doctor wearing a white lab coat shrugs his shoulders and holds his hands up in the air looking confused
Healthcare Shares

Are healthy returns on the horizon for ASX 200 healthcare shares in 2023?

Will the healthcare sector make a full recovery from COVID this year?

Read more »

Two children hold on tightly to books hugged against their chests, as if they were holding on to ASX shares for the long term.
Investing Strategies

16% dividend yield: Fund names 2 slammed ASX shares to buy for the long run

If you're in a skittish market, then the trick is not to become skittish yourself. Here's a pair of quality…

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why ANZ, Australian Clinical Labs, Core Lithium, and Kogan are sinking today

These ASX shares are sinking on Thursday...

Read more »

A man wearing a white coat and glasses is wide-mouthed in surprise.
Healthcare Shares

Another ASX All Ords share is plunging 12% on cyberattack news

This pathology services provider has revealed that it was hit by a cyberattack in February...

Read more »

Two cute young children, a boy and a girl, sit on a sofa together with eager looks on their faces as the boy holds a remote control in one hand.
Broker Notes

'Bright outlook': Expert picks 2 ASX shares that touch Aussies everyday

Brands that Australians use everyday can be a great place to start when coming up with stocks to invest in…

Read more »

A man sits in deep thought with a pen held to his lips as he ponders his computer screen with a laptop open next to him on his desk in a home office environment.
Dividend Investing

3 ASX All Ordinaries shares trading ex-dividend today

These shares are underperforming today. Here's why.

Read more »

Green arrow going up on stock market chart, symbolising a rising share price.
Share Gainers

Why Australian Clinical Labs, Lake Resources, PolyNovo, and ResApp are rising

These ASX shares are pushing higher despite the market selloff...

Read more »

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Why these 3 ASX healthcare shares could get a boost from the federal budget

We check whether additional funding for COVID-19 testing might impact these ASX shares?

Read more »

A man wearing a white coat and glasses is wide-mouthed in surprise.
Earnings Results

Australian Clinical Labs (ASX:ACL) share price falls despite tripling profits and beating guidance

This healthcare share had a strong half..

Read more »

Dividend Payment History Data provided by Morningstar.

Data provided by Morningstar.
Ex-Date Amount Franking Type Payable
12 Mar 2026 $0.0375 100.00% Interim 31 Mar 2026
01 Sep 2025 $0.0900 100.00% Final 23 Sep 2025
27 Mar 2025 $0.0350 100.00% Interim 16 Apr 2025
04 Sep 2024 $0.0900 100.00% Final 27 Sep 2024
28 Mar 2024 $0.0300 100.00% Interim 26 Apr 2024
27 Mar 2023 $0.0700 100.00% Interim 26 Apr 2023
23 Aug 2022 $0.4100 100.00% Final 15 Sep 2022
25 Mar 2022 $0.1200 100.00% Interim 21 Apr 2022

ACL ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Australian Clinical Labs Ltd

Australian Clinical Labs is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well established in the states of Western Australia, South Australia, Victoria, and the Northern Territory.

ACL Share Price History Data provided by Morningstar.

Data provided by Morningstar.
Date Close Change % Change Volume Open High Low
22 Apr 2026 $2.02 $-0.05 -2.42% 216,702 $2.07 $2.07 $2.01
21 Apr 2026 $2.07 $-0.02 -0.96% 514,139 $2.07 $2.10 $2.04
20 Apr 2026 $2.09 $0.00 0.00% 592,074 $2.10 $2.10 $2.05
17 Apr 2026 $2.09 $0.01 0.48% 773,308 $2.09 $2.11 $2.06
16 Apr 2026 $2.08 $0.06 2.97% 1,643,982 $2.02 $2.10 $2.02
15 Apr 2026 $2.02 $0.01 0.50% 343,360 $2.02 $2.05 $2.01
14 Apr 2026 $2.01 $-0.01 -0.50% 524,705 $2.05 $2.06 $2.01
13 Apr 2026 $2.02 $-0.05 -2.42% 1,444,955 $2.06 $2.10 $2.02
10 Apr 2026 $2.07 $0.01 0.49% 322,420 $2.05 $2.08 $2.03
09 Apr 2026 $2.06 $-0.01 -0.48% 1,021,647 $2.09 $2.09 $2.05
08 Apr 2026 $2.07 $0.02 0.98% 510,135 $2.06 $2.11 $2.06
07 Apr 2026 $2.05 $0.02 0.99% 555,022 $2.02 $2.05 $2.02
02 Apr 2026 $2.03 $-0.01 -0.49% 1,994,549 $2.04 $2.05 $2.00
01 Apr 2026 $2.04 $-0.04 -1.92% 881,800 $2.11 $2.11 $2.03
31 Mar 2026 $2.08 $0.06 2.97% 1,222,587 $2.02 $2.11 $2.02
30 Mar 2026 $2.02 $0.00 0.00% 593,149 $2.03 $2.05 $2.00
27 Mar 2026 $2.02 $-0.04 -1.94% 339,464 $2.04 $2.06 $2.01
26 Mar 2026 $2.06 $0.04 1.98% 484,266 $2.04 $2.06 $2.01
25 Mar 2026 $2.02 $0.06 3.07% 380,827 $1.97 $2.04 $1.96
24 Mar 2026 $1.96 $0.02 1.03% 316,343 $1.96 $1.97 $1.92

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
19 Feb 2026 Sarah Butler Buy 22,617 $49,983
On-market trade. Average consideration of $2.21 per share
28 Oct 2025 Stephen Roche Buy 70,000 $193,900
On-market trade.

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Stephen Patrick Roche Non-Executive DirectorNon-Executive Chairman Jun 2025
Mr Roche has strategic and operational experience across several industry sectors including healthcare, retail, building materials and fast-moving consumer goods. Stephen has over 15 years' experience as a director of public companies, not-for-profits and private family offices, having held executive roles as the Managing Director and CEO of Australian Pharmaceutical Industries Limited and Bridgestone Australia & New Zealand. Stephen is currently a Director of the Adelaide Football Club. Stephen was formerly a Non-Executive Director of Myer Family Investments Ltd. He also established and was Chair of the Priceline Sisterhood Foundation from 2015, before retiring in 2018. The foundation, with its mission of creating positive health outcomes and support for women, became the official charity for all Wesfarmers Health businesses from 2025.
Ms Christine Nildra Bartlett Non-Executive Director Aug 2023
Ms Bartlett is an experienced Non-Executive Director, with executive experience gained through chief executive officer and senior executive roles with National Australia Bank Limited, IBM and Jones Lang LaSalle. Christine has held roles with national and global responsibilities and has a commercial perspective, in fostering innovation and leveraging new emerging technologies. Christine is currently the Chair of CEDA and a Non-Executive Director of Mirvac Limited, TAL Life Limited and Reliance Worldwide Corporation Limited. Christine is a member of the UNSW Australian School of Business Advisory Council. Christine has previously held Non-Executive Director roles with iCare NSW, Clayton Utz, GBST Holdings Limited, The Smith Family and Sigma Healthcare Limited. She is member of Risk Committee.
Mr Mark Haberlin Non-Executive Director Apr 2021
Mr Haberlin has over 25 years of audit, risk management, capital transactions and mergers and acquisitions experience across industries including healthcare, real estate and financial services. Mark is the Lead Independent Director and Chair of the Audit and Risk Committee of Abacus Property Group. Previously, Mark was an independent Non-Executive Director and the Chair of the Audit and Risk Committee of Laybuy Group Holdings Limited, the Chair of PwC Australia and PwC's Public Reporting Panel, as well as a Director of the European Australia Business Council and PwC Asia Pacific. He is chair of Risk Committee.
Ms Melinda Leigh McGrath Chief Executive OfficerExecutive Director Dec 2020
Ms McGrath has more than 30 years' experience in healthcare with over 25 years of experience in chief executive roles and over 15 years of experience in pathology CEO roles. Melinda has led the organisation's restructure and transformation, building ACL's scale and operational performance improvement over the past seven years, overseeing the integration of Healthscope's Australian pathology business, St John of God Health Care's pathology business, Perth Pathology, SunDoctors and MedLab Pathology. She has also driven the establishment of one performance oriented culture across the organisation, via one unified integrated pathology system. Melinda was Chief Executive Officer of QML Pathology (part of Healius/ Primary Healthcare) from 2008 to 2015, where she developed five QML brands and established Tasmania Medical Laboratories. Prior to that, Melinda held transformative chief executive roles at private regional and tertiary referral hospitals in Queensland including The Sunshine Coast Private Hospital, St Andrew's War Memorial Hospital and St Stephens Private Hospital. Melinda has held board member positions at Metro North Hospitals and Health Service including Royal Brisbane, Prince Charles, Redcliffe, Caboolture and related health services and a superannuation fund, UC Super.
Ms Sarah Butler Non-Executive Director Feb 2025
Ms Butler has experience in health, insurance, government, consumer and technology industries with a long career in strategy consulting with Booz & Company and subsequently at PwC. Sarah has worked as a strategic advisor in more than 30 countries, including five years spent living and working in China and Asia. Sarah is currently a Non-Executive Director of Lumonus (global healthtech), Insurance Manufacturers of Australia (being a joint venture of IAG and RACV) and The George Institute for Global Health, where she is also the Chair of the People Committee.
Ms Eleanor Padman Company Secretary
-
Matthew Cordingley Chief Financial Officer
-
Eleanor Padman Company Secretary
-

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Citicorp Nominees Pty Limited 56,401,782 28.81%
HSBC Custody Nominees (Australia) Limited 49,496,460 25.28%
J P Morgan Nominees Australia Pty Limited 31,611,161 16.15%
BNP Paribas Nominees Pty Ltd 5,010,540 2.56%
National Nominees Limited 2,969,871 1.52%
UBS Nominees Pty Limited 2,670,859 1.36%
Melinda McGrath 2,173,867 1.10%
Neweconomy Com Au Nominees Pty Limited 2,144,321 1.10%
BNP Paribas Nominees Pty Ltd i 1,508,979 0.77%
Warbont Nominees Pty Ltd 1,469,081 0.75%
Merrill Lynch (Australia) Nominees Pty Limited 1,421,218 0.73%
Ecapital Nominees Pty Limited 1,352,591 0.70%
ACL Employee Share Trusco Pty Ltd 1,268,956 0.65%
HSBC Custody Nominees (Australia) Limited i 836,267 0.43%
Zachary Investments Pty Ltd 800,000 0.41%
Anthony Friedli 754,390 0.39%
A.C.N. 633 176 100 Pty Ltd 749,464 0.38%
HSBC Custody Nominees (Australia) Limited GSI EDA 612,905 0.31%
HSBC Custody Nominees (Australia) Limited Gsco Eca 572,267 0.29%
Pacific Custodians Pty Limited 550,845 0.28%

Profile

since

Note